Pharmacogenomics for Improving Pediatric ADHD Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-28

Study Completion Date

2020-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research study is a randomized controlled trial (RCT) to test whether pharmacogenomics (PGx) testing for ADHD medications will help guide clinicians to choose medications and dosages for pediatric ADHD treatment that provide faster symptom relief, fewer or less severe side effects, improve patient quality of life, and lessen emotional stress for parents/guardians of the patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacogenomics of Stimulant Treatment Response

NCT06221358

Attention-Deficit/ Hyperactivity Disorder (ADHD)

RECRUITING

Candidate Gene Screening for Attention Deficit/Hyperactive Disorder (ADHD)

NCT03018574

Gene Product Sequence Variation

COMPLETED

Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00409708

Attention Deficit Hyperactivity Disorder

COMPLETED PHASE2

Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder

NCT00916786

Attention Deficit Hyperactivity Disorder

COMPLETED

Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)

NCT00483106

Attention Deficit Hyperactivity Disorder

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a randomized controlled trial (RCT) of pediatric Attention Deficit Hyperactivity Disorder (ADHD) patients using an experimental group and a control group. The subjects in the experimental group will be administered a commercially available pharmacogenomics (PGx) test panel of 38 genes specifically related to drug metabolism rates and drug response. A subset of these genes are known to be involved in the pharmacokinetics and pharmacodynamics of ADHD medications.

The PGx test report indicates if there are genetic variants detected related to ADHD medications and consequently provides recommendations for the clinician on which medications and doses may be optimally effective. The control group is the "treatment as usual" (TAU) group whose subjects are treated with medications for ADHD based on the treating clinician's customary method(s) for selecting medications and doses.

The hypotheses to be tested are that PGx testing guidance will reduce the time it takes to reach a treatment regimen that improves patient symptom relief, reduces the frequency and severity of adverse drug reactions, improves patient quality of life, and reduces parental emotional stress. Additionally, since the test is performed using next-generation sequencing, we wish to tabulate relevant allele frequencies and use variant call files to discover previously unknown PGx genetic variants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention Deficit Disorders With Hyperactivity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants will be randomized to have their study clinician have access to their pharmacogenomics report prior to prescribing medications (experimental group) or no access (control group) until end of the study.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Subjects will be blinded as to study arm participation and outcome assessments.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pharmacogenomics report

Clinician reviews pharmacogenomics report for subject prior to prescribing FDA-approved medications.

Group Type EXPERIMENTAL

Pharmacogenomics report

Intervention Type DIAGNOSTIC_TEST

Intervention is the performance of a pharmacogenomics laboratory-developed test (LDT) performed by high-throughput sequencing of 38 genes involved in drug pharmacokinetics or pharmacodynamics. The clinician reviews the report results for each subject.

Control

Clinician prescribes FDA-approved medications as customarily performed without additional guidance from pharmacogenomics report ("treatment-as-usual").

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pharmacogenomics report

Intervention is the performance of a pharmacogenomics laboratory-developed test (LDT) performed by high-throughput sequencing of 38 genes involved in drug pharmacokinetics or pharmacodynamics. The clinician reviews the report results for each subject.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female between the ages of 6 and 18 inclusive at the start of the study.
* Provision of signed and dated informed consent form.
* Subject and parent or legal guardian must state willingness to comply with all study procedures and availability for the duration of the study.
* Both male and female subjects will be recruited from the pediatric population diagnosed with any subtype of ADHD without Oppositional Defiant Disorder (ODD) via the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria.
* Subject and their parent or legal guardian will read and speak English with sufficient proficiency to understand the study and be able to give informed assent and consent.
* Subject will be able to complete study procedures such as filling out paper quality of life assessments
* Subjects will be able to take oral medication(s) if and as prescribed.
* Agreement to adhere to Lifestyle Considerations throughout study duration.

Exclusion Criteria

* Subjects will not have been treated for any condition with psychiatric prescription medications within the previous six (6) months.
* Subjects will not have had a diagnosis of Oppositional Defiant Disorder (ODD).
* Subject will not be currently a suicide risk, has previously made a suicide attempt or has a prior history of suicidal behavior.
* Subject will not have a history of alcohol or other substance abuse or dependence within the last 6 months.
* Subject will not have used an investigational medicinal product or participation in a clinical study within six (6) months prior to the baseline visit.
* Subject will not have a clinically important abnormality on urine drug and alcohol screen, if one had been taken.
* If the subject is female, is not currently pregnant, reasonably expecting to become pregnant, or lactating.
* Subject will not have a known or suspected allergy to any of the potential medications that may be prescribed.
* Only one subject per family will be enrolled to prevent systematic bias based on a parent or legal guardian's personal style of symptom assessment.

Minimum Eligible Age

6 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No